A client with a history of relapsing-remitting multiple sclerosis (RRMS) has been prescribed glatiramer acetate (Copaxone). Which statement by the client indicates a correct understanding of the medication?

A. Glatiramer acetate modulates the immune system by shifting T-cell responses from pro-inflammatory to anti-inflammatory activity, reducing the immune attack on myelin. This helps decrease the frequency of relapses in RRMS without broadly suppressing the immune system. B. Frequent blood draws for liver function monitoring are not required for glatiramer acetate, unlike some other disease-modifying therapies such as interferon beta or teriflunomide. Routine labs are minimal because this medication has a favorable safety profile. C. Glatiramer acetate does not suppress the entire immune system. Unlike some immunosuppressive drugs, it specifically modulates immune responses rather than causing generalized immunosuppression, which helps reduce infection risk. D. This medication does not cure multiple sclerosis. It is disease-modifying, meaning it helps reduce relapse frequency and slows disease progression but cannot reverse existing damage or completely eliminate the disease.